Longitudinal association between N-terminal B-type natriuretic peptide, anxiety and social support in patients with HFpEF: results from the multicentre randomized controlled Aldo-DHF trial

Table 3 Regression analyses to predict HADS-anxiety at baseline and follow-up by baseline NT-proBNP for male patients

Dependent variable	Model	Predictor	β	p value	Corrected R² (p-value)
HADS anxiety baseline	Model 1 Model 2	NT-proBNP	− 0.165	0.028	0.022 (0.028) 0.238 (< 0.001)
		NT-proBNP	− 0.080	0.270
		Age	− 0.108	0.134
		Social support	− 0.312	< 0.001
		Physical function	− 0.320	< 0.001
HADS anxiety 12 m	Model 1 Model 2	NT-proBNP	− 0.149	0.050	0.022 (0.058) 0.286 (< 0.001)
		NT-proBNP	− 0.068	0.365
		Age	− 0.033	0.657
		Social support	− 0.367	< 0.001
		Physical function	− 0.361	< 0.001
		Study arm	− 0.161	0.021

β standardized regression coefficient; p p value; R² coefficient of determination; HADS Hospital Anxiety and Depression Scale; log NT-proBNP log-transformed N-terminal pro brain natriuretic peptide; 12 m after 12 months; Social Support ENRICHD Social Support Inventory; Physical Function subscale from Short Form Health Survey 36; study arm: reference = control group

ISSN: 1471-2261